ORCID Profile
0000-0003-1212-269X
Current Organisations
St George Hospital
,
UNSW Sydney
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Mucosa
Date: 31-01-2023
Abstract: Exfoliative cheilitis is an inflammatory condition that can significantly impair quality of life. This is the first reported case of an interleukin-23 inhibitor, tildrakizumab, for the treatment of a chronic, refractory case of exfoliative cheilitis.
Publisher: Oxford University Press (OUP)
Date: 2023
DOI: 10.1093/CED/LLAC137
Abstract: Glucocorticoid use in patients with autoimmune bullous disease is associated with significant morbidity, and in some cases, excess mortality. The hyperglycaemic complications arising from glucocorticoid use have been well-documented and range from mild hyperglycaemia to diabetic ketoacidosis. Patients with pre-existing glucose intolerance or type 2 diabetes mellitus are at increased risk of developing complications. Several other factors have been investigated for their association with steroid-induced hyperglycaemia, including patient age, sex, family history, dose, regimen and duration of therapy. Findings in the current literature, however, are largely conflicting and evidence is limited by methodological weaknesses. Glucocorticoids should be used with caution, and patients using steroids should be closely monitored for adverse effects.
Publisher: Oxford University Press (OUP)
Date: 12-07-2023
DOI: 10.1093/CED/LLAD215
Abstract: Our case series findings indicate that tildrakizumab treatment in patients with hidradenitis suppurativa who previously received adalimumab demonstrated an initial improvement in disease activity within the first 6 months. However, this overall trend was not sustained beyond the 6-month mark. Nevertheless, it is noteworthy that patients who underwent long-term follow-up on tildrakizumab experienced ongoing disease activity but showed a reduction in Dermatology Life Quality Index scores.
Publisher: BMJ
Date: 29-09-2018
DOI: 10.1136/EMERMED-2017-206637
Abstract: The utilisation of medical scribes in the USA has enabled productivity gains for emergency consultants, though their personal experiences have not been widely documented. We aimed to evaluate the consultant experience of working with scribes in an Australian ED. Emergency consultants working with scribes and those who declined to work with scribes were invited to participate in in idual interviews (structured and semistructured questions) about scribes, scribe work and the scribe program in October 2016. Of 16 consultants, 13 participated in interviews, that is, 11 worked with scribes and 2 did not and 3 left Cabrini prior to the interviews. Consultants working with scribes found them most useful for capturing initial patient encounters, for finding information and completing discharge tasks. Scribes captured more details than consultants usually did. Editing was required for omissions, misunderstandings and rearranging information order, but this improved with increasing scribe experience. Consultants described changing their style to give more information to the patient in the room. Consultants felt more productive and able to meet demands. They also described enjoyment, less stress, less cognitive loading, improved ability to multitask, see complex patients and less fatigue. In interviews with the two consultants declining scribes, theme saturation was not achieved. Consultants declining scribes preferred to work independently. They did not like templated notes and felt that consultation nuances were lost. They valued their notes write-up time as time for cognitive processing of the presentation. They thought the scribe and computer impacted negatively on communication with the patient. Medical scribes were seen to improve physician productivity, enjoyment at work, ability to multitask and to lower stress levels. Those who declined scribes were concerned about losing important nuances and cognitive processing time for the case.
Publisher: Wiley
Date: 04-08-2020
DOI: 10.1111/BJU.15124
Publisher: Wiley
Date: 22-02-2023
DOI: 10.1111/AJD.14001
Abstract: Vitiligo is an autoimmune skin disorder resulting in the depigmentation of skin characterised by patches of varying sizes and shapes. A common disorder of pigmentation that affects 0.5%–2% of the global population. Despite its well‐understood autoimmune pathogenesis, the targets for effective cytokine intervention remain unclear. Current first‐line treatments include oral or topical corticosteroids, calcineurin inhibitors and phototherapy. These treatments are limited, have varying efficacies, and are associated with significant adverse events or can be time‐consuming. Therefore, biologics should be explored as a potential treatment for vitiligo. There are currently limited data for the use of JAK and IL‐23 inhibitors for vitiligo. A total of 25 studies were identified in the review. There is promising evidence regarding the use of JAK and IL‐23 inhibitors for the treatment of vitiligo.
Publisher: Wiley
Date: 24-04-2022
DOI: 10.1111/COD.14125
Publisher: Wiley
Date: 28-07-2022
DOI: 10.1111/JDV.18451
Publisher: Wiley
Date: 16-05-2022
DOI: 10.1111/AJD.13864
Publisher: Mucosa
Date: 31-05-2022
Abstract: Bullous pemphigoid has been described in a small number of cases secondary to the Pfizer and Moderna COVID-19 vaccinations. This is the first reported case of bullous pemphigoid triggered by the Oxford-AstraZeneca Vaxzevria COVID-19 vaccination. His first symptoms occurred four weeks after his first dose, and were confirmed on direct immunofluorescence and with positive BP180 antibodies.
No related grants have been discovered for Timothy Luke Cowan.